Cresset, innovative provider of software and contract services for small molecule discovery and design, is pleased to announce that this week, Dr Robert Scoffin, CEO, will chair the‘Sym 203: Pioneering Screening Technologies for Lead Compounds’ session at the Annual Congress of Medichem in Nanjing, China.
Cresset CEO chairs and presents at International Congress of Medichem, China
Dr Scoffin will also present an overview of virtual screening methods for drug discovery.
The virtual screening of molecules is a commonly used technique within pharmaceutical drug discovery, and has many applications including the selection of compounds for ‘wet screening’ and the design of novel libraries of compounds.
“Cresset is a market leader in virtual screening,” says Dr Scoffin. “Blaze is an effective ligand-based virtual screening platform used by pharmaceutical companies globally. Blaze is also used by Cresset Discovery Services who carry out virtual screening in many consultancy projects. I am looking forward to sharing thevarious methods employed within a virtual screening cascade, including 2D methods, 3D ligand-based methodsand 3D structure-based methods, and describing how each of these contributes to the overall value of the virtual screening process.”
Annual Congress of Medichem: 16-19 November 2016
Cresset’s software and discovery research services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavour, fragrance and pharmaceuticals. For more information visit www.cresset-group.com
Sue Peffer, Marketing Manager, email@example.com, +44 (0)1223 858890
Computational solutions for drug discovery